{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Disease&page=10",
    "query": {
      "condition": "Liver Disease",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 4307,
    "total_pages": 431,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Disease&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Disease&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T02:14:23.770Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05720663",
      "title": "Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2023-04-19",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Richmond, Virginia",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05720663"
    },
    {
      "nct_id": "NCT03823144",
      "title": "Intravital Microscopy in Human Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Malignant Solid Neoplasm",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Primary Malignant Brain Neoplasm",
        "Metastatic Sarcoma",
        "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8",
        "Resectable Colorectal Carcinoma",
        "Resectable Liver and Intrahepatic Bile Duct Carcinoma",
        "Resectable Pancreatic Carcinoma",
        "Resectable Sarcoma",
        "Stage IV Colorectal Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Malignant Brain Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Liver Carcinoma",
        "Metastatic Pancreatic Carcinoma",
        "Resectable Brain Neoplasm",
        "Resectable Breast Carcinoma",
        "Resectable Gastric Carcinoma",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Diagnostic Microscopy",
          "type": "DEVICE"
        },
        {
          "name": "Fluorescein Sodium Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2019-02-28",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823144"
    },
    {
      "nct_id": "NCT00141999",
      "title": "Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis"
      ],
      "interventions": [
        {
          "name": "hepatitis B vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "5 Years to 14 Years"
      },
      "enrollment_count": 400,
      "start_date": "2001-05",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2012-09-27",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 1,
      "location_summary": "Anchorage, Alaska",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141999"
    },
    {
      "nct_id": "NCT01100398",
      "title": "Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "possible liver biopsy and serum collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Brooke Army Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 400,
      "start_date": "2007-01",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2010-12-24",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100398"
    },
    {
      "nct_id": "NCT04102098",
      "title": "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 668,
      "start_date": "2019-12-31",
      "completion_date": "2026-05-15",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04102098"
    },
    {
      "nct_id": "NCT00680342",
      "title": "Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Silymarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2008-04",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2013-03-18",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680342"
    },
    {
      "nct_id": "NCT03126370",
      "title": "Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C",
        "HIV Coinfection"
      ],
      "interventions": [
        {
          "name": "TDF with a boosted protease inhibitor",
          "type": "DRUG"
        },
        {
          "name": "TAF with a boosted protease inhibitor",
          "type": "DRUG"
        },
        {
          "name": "TAF with a boosted protease inhibitor and LDV/SOF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-01-08",
      "completion_date": "2019-10-01",
      "has_results": true,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126370"
    },
    {
      "nct_id": "NCT01644656",
      "title": "Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Portal Hypertension",
        "Chronic Liver Disease"
      ],
      "interventions": [
        {
          "name": "ARFI ultrasound",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "VA Connecticut Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 500,
      "start_date": "2012-07",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • West Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644656"
    },
    {
      "nct_id": "NCT03067129",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus (HCV)"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir Adult Formulation",
          "type": "DRUG"
        },
        {
          "name": "Glecaprevir + Pibrentasvir Pediatric Formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 129,
      "start_date": "2017-03-20",
      "completion_date": "2022-09-12",
      "has_results": true,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03067129"
    },
    {
      "nct_id": "NCT06109272",
      "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Livmoniplimab",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2024-01-11",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-21T02:14:23.770Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Irvine, California • Orange, California + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Merriam",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06109272"
    }
  ]
}